CGON insider sale notice: 27,015 shares via Morgan Stanley on NASDAQ
Rhea-AI Filing Summary
CG Oncology, Inc. (CGON) filing a Form 144 to report a proposed sale of common stock. The notice shows 27,015 shares to be sold through Morgan Stanley Smith Barney LLC on 09/05/2025 on NASDAQ with an aggregate market value of $835,844.10 and 76,247,581 shares outstanding. The securities were acquired on 09/05/2025 by exercise of stock options from the issuer, paid in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale notice reporting option exercise and planned sale of 27,015 shares.
This Form 144 documents a proposed sale tied to an option exercise on the same date, routed through Morgan Stanley Smith Barney LLC for execution on NASDAQ, with an aggregate market value of $835,844.10. The filing indicates no other sales in the past three months and includes the standard attestation about material non-public information. The disclosure appears procedural and consistent with compliance reporting for insiders monetizing exercised options.
TL;DR: Compliance-focused filing; shows standard representations and broker details for planned disposal.
The notice provides the issuer, broker, quantity, acquisition method (stock option exercise), payment type (cash), and execution venue. It contains the usual signature attestation regarding material information and a blank remark section. From a governance perspective this is a standard Form 144 notification to satisfy Rule 144 requirements.